Oppenheimer Asset Management Inc. Has $369,000 Stake in Ironwood Pharmaceuticals, Inc. (IRWD)

Oppenheimer Asset Management Inc. grew its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 30.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,405 shares of the biotechnology company’s stock after purchasing an additional 5,527 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Ironwood Pharmaceuticals were worth $369,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Gerber Kawasaki Wealth & Investment Management bought a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at $170,000. Teacher Retirement System of Texas bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at $192,000. Strs Ohio boosted its stake in Ironwood Pharmaceuticals by 63.1% during the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 4,100 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 648 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in Ironwood Pharmaceuticals by 11.9% during the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 1,410 shares in the last quarter.

Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at $15.72 on Monday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $13.43 and a 12 month high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The firm had revenue of $86.80 million for the quarter, compared to the consensus estimate of $73.59 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The business’s revenue was up 31.3% on a year-over-year basis. sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 115,769 shares of company stock worth $1,752,491. Corporate insiders own 7.63% of the company’s stock.

Several research analysts recently issued reports on IRWD shares. Cowen set a $20.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 21st. BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Mizuho reissued a “buy” rating and set a $20.00 target price (down from $23.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, August 25th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Credit Suisse Group started coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, November 27th. They set a “buy” rating and a $19.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $17.88.

TRADEMARK VIOLATION WARNING: “Oppenheimer Asset Management Inc. Has $369,000 Stake in Ironwood Pharmaceuticals, Inc. (IRWD)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/12/18/oppenheimer-asset-management-inc-has-369000-stake-in-ironwood-pharmaceuticals-inc-irwd.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply